Antibody replacement therapy in primary antibody deficiencies and iatrogenic hypogammaglobulinemia

References

• Edgar JD, Buckland M, Guzman D, et al. The united kingdom primary immune deficiency (UKPID) registry: Report of the first 4 years’ activity 2008-2012. Clin Exp Immunol 2014;175(1):68-78
   PubMed Web of Science ®Google Scholar
• Jonkman-Berk BM, van den Berg JM, Ten Berge IJ, et al. Primary immunodeficiencies in the netherlands: National patient data demonstrate the increased risk of malignancy. Clin Immunol 2014;156(2):154-62
   Google Scholar
• Ludviksson BR, Sigurdardottir ST, Johannsson JH et al. Epidemiology of primary immunodeficiency in iceland. J Clin Immunol 2014. [ Epub ahead of print
   Google Scholar
• Boyle JM, Buckley RH. Population prevalence of diagnosed primary immunodeficiency diseases in the united states. J Clin Immunol 2007;27(5):497-502
   PubMed Web of Science ®Google Scholar
• Samson M, Audia S, Lakomy D, et al. Diagnostic strategy for patients with hypogammaglobulinemia in rheumatology. Joint Bone Spine 2011;78(3):241-5
   Google Scholar
• Compagno N, Malipiero G, Cinetto F, Agostini C. Immunoglobulin replacement therapy in secondary hypogammaglobulinemia. Front Immunol 2014;5:626
   PubMed Web of Science ®Google Scholar
• Blot M, Boyer P, Samson M, et al. Should mild hypogammaglobulinemia be managed as severe hypogammaglobulinemia? A study of 389 patients with secondary hypogammaglobulinemia. Eur J Intern Med 2014;25(9):837-42
   Google Scholar
• Duraisingham SS, Buckland MS, Grigoriadou S, Longhurst HJ. Secondary antibody deficiency. Expert Rev Clin Immunol 2014;10(5):583-91
   PubMed Web of Science ®Google Scholar
• Novosad SA, Winthrop KL. Beyond tumor necrosis factor inhibition: The expanding pipeline of biologic therapies for inflammatory diseases and their associated infectious sequelae. Clin Infect Dis 2014;58(11):1587-98
   PubMed Web of Science ®Google Scholar
• Bruton OC. Agammaglobulinemia. Pediatrics 1952;9(6):722-8
   PubMed Web of Science ®Google Scholar
• Bonilla FA, Bernstein IL, Khan DA, et al. Practice parameter for the diagnosis and management of primary immunodeficiency. Ann Allergy Asthma Immunol 2005;94(5 Suppl 1):S1-63
   PubMed Web of Science ®Google Scholar
• Shehata N, Palda V, Bowen T, et al. The use of immunoglobulin therapy for patients with primary immune deficiency: An evidence-based practice guideline. Transfus Med Rev 2010;24(suppl 1):S28-50
   PubMed Web of Science ®Google Scholar
• Yong PL, Boyle J, Ballow M, et al. Use of intravenous immunoglobulin and adjunctive therapies in the treatment of primary immunodeficiencies: A working group report of and study by the primary immunodeficiency committee of the american academy of allergy asthma and immunology. Clin Immunol 2010;135(2):255-63
   PubMed Web of Science ®Google Scholar
• Durandy A, Kracker S, Fischer A. Primary antibody deficiencies. Nat Rev Immunol 2013;13(7):519-33
   PubMed Web of Science ®Google Scholar
• Roberts DM, Jones RB, Smith RM, et al. Rituximab-associated hypogammaglobulinemia: Incidence, predictors and outcomes in patients with multi-system autoimmune disease. J Autoimmun 2015;57:60-5
   PubMed Web of Science ®Google Scholar
• Wood PM, Mayne A, Joyce H, et al. A mutation in bruton’s tyrosine kinase as a cause of selective anti-polysaccharide antibody deficiency. J Pediatr 2001;139(1):148-51
   Google Scholar
• Abolhassani H, Sagvand BT, Shokuhfar T, et al. A review on guidelines for management and treatment of common variable immunodeficiency. Expert Rev Clin Immunol 2013;9(6):561-74; quiz 575
   PubMed Web of Science ®Google Scholar
• Poodt AE, Driessen GJ, de Klein A, et al. TACI mutations and disease susceptibility in patients with common variable immunodeficiency. Clin Exp Immunol 2009;156(1):35-9
   Google Scholar
• Nelson KS, Lewis DB. Adult-onset presentations of genetic immunodeficiencies: Genes can throw slow curves. Curr Opin Infect Dis 2010;23(4):359-64
   Google Scholar
• Yong PF, Thaventhiran JE, Grimbacher B. "A rose is a rose is a rose," but CVID is not CVID common variable immune deficiency (CVID), what do we know in 2011? Adv Immunol 2011;111:47-107
   PubMed Web of Science ®Google Scholar
• Zen M, Canova M, Campana C, et al. The kaleidoscope of glucorticoid effects on immune system. Autoimmun Rev 2011;10(6):305-10
   PubMed Web of Science ®Google Scholar
• Klaustermeyer WB, Gianos ME, Kurohara ML, et al. IgG subclass deficiency associated with corticosteroids in obstructive lung disease. Chest 1992;102(4):1137-42
   Google Scholar
• Kawano T, Matsuse H, Obase Y, et al. Hypogammaglobulinemia in steroid-dependent asthmatics correlates with the daily dose of oral prednisolone. Int Arch Allergy Immunol 2002;128(3):240-3
   PubMed Web of Science ®Google Scholar
• Mogensen TH, Bernth-Jensen JM, Petersen CC, et al. Common variable immunodeficiency unmasked by treatment of immune thrombocytopenic purpura with rituximab. BMC Hematol 2013;13(1):4-1839; 13-4
   PubMedGoogle Scholar
• van Vollenhoven RF, Emery P, Bingham CO3rd, et al. Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann Rheum Dis 2013;72(9):1496-502
   PubMed Web of Science ®Google Scholar
• Levy R, Mahevas M, Galicier L, et al. Profound symptomatic hypogammaglobulinemia: A rare late complication after rituximab treatment for immune thrombocytopenia. report of 3 cases and systematic review of the literature. Autoimmun Rev 2014;13(10):1055-63
   PubMed Web of Science ®Google Scholar
• De La Torre I, Leandro MJ, Valor L, et al. Total serum immunoglobulin levels in patients with RA after multiple B-cell depletion cycles based on rituximab: Relationship with B-cell kinetics. Rheumatology (Oxford) 2012;51(5):833-40
   PubMed Web of Science ®Google Scholar
• Isvy A, Meunier M, Gobeaux-Chenevier C, et al. Safety of rituximab in rheumatoid arthritis: A long-term prospective single-center study of gammaglobulin concentrations and infections. Joint Bone Spine 2012;79(4):365-9
   Google Scholar
• Kano G, Nakatani T, Yagi K, et al. Complicated pathophysiology behind rituximab-induced persistent hypogammaglobulinemia. Immunol Lett 2014;159(1-2):76-8
   PubMed Web of Science ®Google Scholar
• Kuijpers TW, Bende RJ, Baars PA, et al. CD20 deficiency in humans results in impaired T cell-independent antibody responses. J Clin Invest 2010;120(1):214-22
   PubMed Web of Science ®Google Scholar
• Mawhorter S, Yamani MH. Hypogammaglobulinemia and infection risk in solid organ transplant recipients. Curr Opin Organ Transplant 2008;13(6):581-5
   Google Scholar
• Karnell JL, Karnell FG3rd, Stephens GL, et al. Mycophenolic acid differentially impacts B cell function depending on the stage of differentiation. J Immunol 2011;187(7):3603-12
   Google Scholar
• Florescu DF, Kalil AC, Qiu F, et al. What is the impact of hypogammaglobulinemia on the rate of infections and survival in solid organ transplantation? A meta-analysis. Am J Transplant 2013;13(10):2601-10
   PubMed Web of Science ®Google Scholar
• Yip NH, Lederer DJ, Kawut SM, et al. Immunoglobulin G levels before and after lung transplantation. Am J Respir Crit Care Med 2006;173(8):917-21
   PubMed Web of Science ®Google Scholar
• Plebani A, Soresina A, Rondelli R, et al. Clinical, immunological, and molecular analysis in a large cohort of patients with X-linked agammaglobulinemia: An italian multicenter study. Clin Immunol 2002;104(3):221-30
   PubMed Web of Science ®Google Scholar
• Quinti I, Soresina A, Spadaro G, et al. Long-term follow-up and outcome of a large cohort of patients with common variable immunodeficiency. J Clin Immunol 2007;27(3):308-16
   PubMed Web of Science ®Google Scholar
• Park JH, Levinson AI. Granulomatous-lymphocytic interstitial lung disease (GLILD) in common variable immunodeficiency (CVID). Clin Immunol 2010;134(2):97-103
   PubMed Web of Science ®Google Scholar
• Klein NC, Go CH, Cunha BA. Infections associated with steroid use. Infect Dis Clin North Am 2001;15(2):423-32, viii
   PubMed Web of Science ®Google Scholar
• Buch MH, Smolen JS, Betteridge N, et al. Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 2011;70(6):909-20
   PubMed Web of Science ®Google Scholar
• Venhoff N, Effelsberg NM, Salzer U, et al. Impact of rituximab on immunoglobulin concentrations and B cell numbers after cyclophosphamide treatment in patients with ANCA-associated vasculitides. PLoS ONE 2012;7(5):e37626
   PubMed Web of Science ®Google Scholar
• Besada E, Koldingsnes W, Nossent JC. Long-term efficacy and safety of pre-emptive maintenance therapy with rituximab in granulomatosis with polyangiitis: Results from a single centre. Rheumatology (Oxford) 2013;52(11):2041-7
   PubMed Web of Science ®Google Scholar
• Marco H, Smith RM, Jones RB, et al. The effect of rituximab therapy on immunoglobulin levels in patients with multisystem autoimmune disease. BMC Musculoskelet Disord 2014;15:178
   PubMed Web of Science ®Google Scholar
• Mouthon L, Fermand JP, Gottenberg JE. Management of secondary immune deficiencies: What is the role of immunoglobulins? Curr Opin Allergy Clin Immunol 2013;13(suppl 2):S56-67
   PubMedGoogle Scholar
• Yoshizumi T, Shirabe K, Ikegami T, et al. Decreased immunoglobulin G levels after living-donor liver transplantation is a risk factor for bacterial infection and sepsis. Transpl Infect Dis 2014;16(2):225-31
   Google Scholar
• Noell BC, Dawson KL, Seethamraju H. Effect of hypogammaglobulinemia on the incidence of community-acquired respiratory viral infections after lung transplantation. Transplant Proc 2013;45(6):2371-4
   PubMed Web of Science ®Google Scholar
• Goldfarb NS, Avery RK, Goormastic M, et al. Hypogammaglobulinemia in lung transplant recipients. Transplantation 2001;71(2):242-6
   PubMed Web of Science ®Google Scholar
• Doron S, Ruthazer R, Werner BG, et al. Hypogammaglobulinemia in liver transplant recipients: Incidence, timing, risk factors, and outcomes. Transplantation 2006;81(5):697-703
   Google Scholar
• Florescu DF, Kalil AC, Qiu F, et al. Does increasing immunoglobulin levels impact survival in solid organ transplant recipients with hypogammaglobulinemia? Clin Transplant 2014;28(11):1249-55
   Google Scholar
• Engels EA, Pfeiffer RM, Fraumeni JFJr, et al. Spectrum of cancer risk among US solid organ transplant recipients. JAMA 2011;306(17):1891-901
   PubMed Web of Science ®Google Scholar
• de Roux A, Schmidt N, Rose M, et al. Immunogenity of the pneumococcal polysaccharide vaccine in COPD patients. the effect of systemic steroids. Respir Med 2004;98(12):1187-94
   Google Scholar
• Steentoft J, Konradsen HB, Hilskov J, et al. Response to pneumococcal vaccine in chronic obstructive lung disease--the effect of ongoing, systemic steroid treatment. Vaccine 2006;24(9):1408-12
   Google Scholar
• Chen M, Hisatomi Y, Furumoto A, et al. Comparative immune responses of patients with chronic pulmonary diseases during the 2-year period after pneumococcal vaccination. Clin Vaccine Immunol 2007;14(2):139-45
   PubMedGoogle Scholar
• Lack G, Ochs HD, Gelfand EW. Humoral immunity in steroid-dependent children with asthma and hypogammaglobulinemia. J Pediatr 1996;129(6):898-903
   PubMed Web of Science ®Google Scholar
• Bingham CO3rd, Looney RJ, Deodhar A, et al. Immunization responses in rheumatoid arthritis patients treated with rituximab: Results from a controlled clinical trial. Arthritis Rheum 2010;62(1):64-74
   PubMed Web of Science ®Google Scholar
• Eckerle I, Rosenberger KD, Zwahlen M, Junghanss T. Serologic vaccination response after solid organ transplantation: A systematic review. PLoS One 2013;8(2):e56974
   PubMed Web of Science ®Google Scholar
• Orange JS, Hossny EM, Weiler CR, et al. Primary Immunodeficiency Committee of the American Academy of Allergy,Asthma and Immunology. Use of intravenous immunoglobulin in human disease: A review of evidence by members of the primary immunodeficiency committee of the american academy of allergy, asthma and immunology. J Allergy Clin Immunol 2006;117(4 suppl):S525-53
   PubMed Web of Science ®Google Scholar
• Gelfand EW, Ochs HD, Shearer WT. Controversies in IgG replacement therapy in patients with antibody deficiency diseases. J Allergy Clin Immunol 2013;131(4):1001-5
   PubMed Web of Science ®Google Scholar
• Bonagura VR. Using intravenous immunoglobulin (IVIG) to treat patients with primary immune deficiency disease. J Clin Immunol 2013;33(suppl 2):90-4
   Google Scholar
• Lingman-Framme J, Fasth A. Subcutaneous immunoglobulin for primary and secondary immunodeficiencies: An evidence-based review. Drugs 2013;73(12):1307-19
   PubMed Web of Science ®Google Scholar
• Maarschalk-Ellerbroek LJ, Hoepelman IM, Ellerbroek PM. Immunoglobulin treatment in primary antibody deficiency. Int J Antimicrob Agents 2011;37(5):396-404
   PubMed Web of Science ®Google Scholar
• Stiehm ER. Adverse effects of human immunoglobulin therapy. Transfus Med Rev 2013;27(3):171-8
   PubMed Web of Science ®Google Scholar
• Spath PJ, Granata G, La Marra F, et al. On the dark side of therapies with immunoglobulin concentrates: The adverse events. Front Immunol 2015;6:11
   PubMed Web of Science ®Google Scholar
• Lucas M, Lee M, Lortan J, et al. Infection outcomes in patients with common variable immunodeficiency disorders: Relationship to immunoglobulin therapy over 22 years. J Allergy Clin Immunol 2010;125(6):1354-1360.e4
   PubMed Web of Science ®Google Scholar
• Orange JS, Belohradsky BH, Berger M, et al. Evaluation of correlation between dose and clinical outcomes in subcutaneous immunoglobulin replacement therapy. Clin Exp Immunol 2012;169(2):172-81
   PubMed Web of Science ®Google Scholar
• Deane S, Selmi C, Naguwa SM, et al. Common variable immunodeficiency: Etiological and treatment issues. Int Arch Allergy Immunol 2009;150(4):311-24
   PubMed Web of Science ®Google Scholar
• Hamilos DL, Young RM, Peter JB, et al. Hypogammaglobulinemia in asthmatic patients. Ann Allergy 1992;68(6):472-81
   PubMedGoogle Scholar
• Looney RJ, Srinivasan R, Calabrese LH. The effects of rituximab on immunocompetency in patients with autoimmune disease. Arthritis Rheum 2008;58(1):5-14
   PubMedGoogle Scholar
• Roberts DM, Jones RB, Smith RM, et al. Immunoglobulin G replacement for the treatment of infective complications of rituximab-associated hypogammaglobulinemia in autoimmune disease: A case series. J Autoimmun 2015;57:24-9
   PubMed Web of Science ®Google Scholar
• Bader-Meunier B. Rituximab treatment in children: Comment on the review by looney et al. Arthritis Rheum 2008;58(8):2583; author reply 2583-4
   Google Scholar
• Olfat M, Silverman ED, Levy DM. A19: Rituximab therapy has a rapid and durable response for refractory cytopenia in childhood-onset systemic lupus erythematosus. Arthrit Rheumatol 2014;66(suppl 11):S30
   Google Scholar
• Kaplan B, Kopyltsova Y, Khokhar A, et al. Rituximab and immune deficiency: Case series and review of the literature. J Allergy Clin Immunol Pract 2014;2(5):594-600
   PubMed Web of Science ®Google Scholar
• Otremba MD, Adam SI, Price CC, et al. Use of intravenous immunoglobulin to treat chronic bilateral otomastoiditis in the setting of rituximab induced hypogammaglobulinemia. Am J Otolaryngol 2012;33(5):619-22
   Google Scholar
• Unger L, Kampf S, Luthke K, Aringer M. Rituximab therapy in patients with refractory dermatomyositis or polymyositis: Differential effects in a real-life population. Rheumatology (Oxford) 2014;53(9):1630-8
   PubMed Web of Science ®Google Scholar
• Makatsori M, Kiani-Alikhan S, Manson A, et al. Hypogammaglobulinaemia after rituximab treatment- its incidence and outcome. QJM 2014;107(10):821-8
   PubMed Web of Science ®Google Scholar
• Cooper N, Davies EG, Thrasher AJ. Repeated courses of rituximab for autoimmune cytopenias may precipitate profound hypogammaglobulinaemia requiring replacement intravenous immunoglobulin. Br J Haematol 2009;146(1):120-2
   PubMed Web of Science ®Google Scholar
• Patel VL, Mahevas M, Lee SY, et al. Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia. Blood 2012;119(25):5989-95
   PubMed Web of Science ®Google Scholar
• Lim E, Tao Y, White AJ, et al. Hypogammaglobulinemia in pediatric systemic lupus erythematosus. Lupus 2013;22(13):1382-7
   PubMed Web of Science ®Google Scholar
• Adeli MM, Eichner BH, Thornburg C, Williams L. Persistent antibody depletion after rituximab in three children with autoimmune cytopenias. Pediatr Hematol Oncol 2009;26(8):566-72
   PubMed Web of Science ®Google Scholar
• Shehata N, Palda VA, Meyer RM, et al. The use of immunoglobulin therapy for patients undergoing solid organ transplantation: An evidence-based practice guideline. Transfus Med Rev 2010;24(suppl 1):S7-S27
   PubMed Web of Science ®Google Scholar
• Jordan SC, Toyoda M, Kahwaji J, Vo AA. Clinical aspects of intravenous immunoglobulin use in solid organ transplant recipients. Am J Transplant 2011;11(2):196-202
   PubMed Web of Science ®Google Scholar
• Yamani MH, Avery R, Mawhorter SD, et al. The impact of CytoGam on cardiac transplant recipients with moderate hypogammaglobulinemia: A randomized single-center study. J Heart Lung Transplant 2005;24(11):1766-9
   Google Scholar
• Carbone J, Sarmiento E, Del Pozo N, et al. Restoration of humoral immunity after intravenous immunoglobulin replacement therapy in heart recipients with post-transplant antibody deficiency and severe infections. Clin Transplant 2012;26(3):E277-83
   Google Scholar
• Lederer DJ, Philip N, Rybak D, et al. Intravenous immunoglobulin for hypogammaglobulinemia after lung transplantation: A randomized crossover trial. PLoS ONE 2014;9(8):e103908
   Google Scholar
• Claustre J, Quetant S, Camara B, et al. Nonspecific immunoglobulin replacement in lung transplantation recipients with hypogammaglobulinemia: A cohort study taking into account propensity score and immortal time bias. Transplantation 2015;99(2):444-50
   Google Scholar
• Schroeder HWJr, Dougherty CJ. Review of intravenous immunoglobulin replacement therapy trials for primary humoral immunodeficiency patients. Infection 2012;40(6):601-11
   Google Scholar
• Baumann U, Miescher S, Vonarburg C. Immunoglobulin replacement therapy in antibody deficiency syndromes: Are we really doing enough? Clin Exp Immunol 2014;178(suppl 1):83-5
   Google Scholar
• Beaute J, Levy P, Millet V, et al. Economic evaluation of immunoglobulin replacement in patients with primary antibody deficiencies. Clin Exp Immunol 2010;160(2):240-5
   PubMed Web of Science ®Google Scholar
• Membe SK, Ho C, Cimon K, et al. Economic assessment of different modalities of immunoglobulin replacement therapy. Immunol Allergy Clin North Am 2008;28(4):861-74, x
   PubMed Web of Science ®Google Scholar
• Bayry J, Kazatchkine MD, Kaveri SV. Shortage of human intravenous immunoglobulin – reasons and possible solutions. Nat Clin Pract Neurol 2007;3(3):120-1
   PubMedGoogle Scholar
• Guillevin L. Pharmacoeconomics of immunoglobulins and indications for their use. Curr Opin Allergy Clin Immunol 2013;13 Suppl 2:S53-5
   Google Scholar
• Orange JS, Ochs HD, Cunningham-Rundles C. Prioritization of evidence-based indications for intravenous immunoglobulin. J Clin Immunol 2013;33(6):1033-6
   PubMed Web of Science ®Google Scholar
• Sewell WA, Kerr J, Behr-Gross ME, et al. Ig Working Group. European consensus proposal for immunoglobulin therapies. Eur J Immunol 2014;44(8):2207-14
   PubMed Web of Science ®Google Scholar
• Orange JS, Ballow M, Stiehm ER, et al. Use and interpretation of diagnostic vaccination in primary immunodeficiency: A working group report of the basic and clinical immunology interest section of the american academy of allergy, asthma & immunology. J Allergy Clin Immunol 2012;130(3 Suppl):S1-24
   PubMed Web of Science ®Google Scholar
• Diwakar L, Gorrie S, Richter A, et al. Does rituximab aggravate pre-existing hypogammaglobulinaemia? J Clin Pathol 2010;63(3):275-7
   Google Scholar
• Shankar T, Gribowicz J, Crespo M, et al. Subcutaneous IgG replacement therapy is safe and well tolerated in lung transplant recipients. Int Immunopharmacol 2013;15(4):752-5
   Google Scholar
• Compagno N, Cinetto F, Semenzato G, Agostini C. Subcutaneous immunoglobulin in lymphoproliferative disorders and rituximab-related secondary hypogammaglobulinemia: A single-center experience in 61 patients. Haematologica 2014;99(6):1101-6
   PubMed Web of Science ®Google Scholar
• Ballow M. Optimizing immunoglobulin treatment for patients with primary immunodeficiency disease to prevent pneumonia and infection incidence: Review of the current data. Ann Allergy Asthma Immunol 2013;111(6 suppl):S2-5
   PubMed Web of Science ®Google Scholar
• Qamar N, Fuleihan RL. The hyper IgM syndromes. Clin Rev Allergy Immunol 2014;46(2):120-30
   PubMed Web of Science ®Google Scholar
• Connor V. Anti-TNF therapies: A comprehensive analysis of adverse effects associated with immunosuppression. Rheumatol Int 2011;31(3):327-37
   PubMed Web of Science ®Google Scholar
• Edwards CJ. IL-6 inhibition and infection: Treating patients with tocilizumab. Rheumatology (Oxford) 2012;51(5):769-70
   Google Scholar